Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1/2 study
Farge D, Loisel S, Resche-Rigon M, Lansiaux P, Colmegna I, Langlais D, Catney C, Pugnet G, Thibault A, Maria J, Chatelus E, Martin T, Hachulla E, Kheav VD, Lambert N, Wang HC, Michonneau D, Martinaud C, Sensebé L, Tarte K.
The Lancet Rheum. 2022 FEB 4(2)91-104. doi: 10.1016/S2665-9913(21)00326-X. IF 8.1
Quality assessment of a serum and xenofree medium for the expansion of human GMP-grade mesenchymal stromal cells.
Aussel C, Busson E, Vantomme H, Tissèdre F, Peltzer J, Martinaud C.
Submitted to Peer J. IF 3
Intra-articular delivery of full-length antibodies through the use of an in situ forming depot
Fayd’herbe de Maudave A, Leconet W, Toupet K, Constantinides M, Bossis G, De Toledo M, Vialaret J, Hirtz C, Loez-Noriega A, Jorgensen C, Noel D, Louis-Plence P, Grizot S, and Vilalba M.
Journal of Controlled Release 2022 341:578-590. doi: 10.1016/j.jconrel.2021.12.010. IF 9.8